March 5, 2006
- Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Free full text available in HTML and PDF formats.
- Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus.
- Association of schizophrenia and autoimmune diseases: linkage of Danish national registers.
- Cerebral glutamate metabolism during hypoglycaemia in healthy and type 1 diabetic humans.
- Early diabetic complications in a population of young patients with type 1 diabetes mellitus despite intensive treatment.
- Age at Onset of Childhood-Onset Type 1 Diabetes and the Development of End-Stage Renal Disease.
- Models for Predicting Type 1 Diabetes in Siblings of Affected Children.
- Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial�Type 1.
- Role of Hepatic Glycogen Breakdown in Defective Counterregulation of Hypoglycemia in Intensively Treated Type 1 Diabetes.
- Increased Monocytic Activity and Biomarkers of Inflammation in Patients With Type 1 Diabetes.
- Gestational Diabetes Identifies Women at Risk for Permanent Type 1 and Type 2 Diabetes in Fertile Age: Predictive role of autoantibodies.
- Is neighbourhood deprivation a risk factor for gestational diabetes mellitus?
- Familial factors in diabetic nephropathy: an offspring study.
- Clinical studies is about pramlintide (Symlin).
- Inhibition of gastric emptying.
- Tissue expression and secretion of amylin.
- Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress status.
- Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study. Free full text available in HTML and PDF formats.
- Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 Diabetes. The Hoorn Study.
- Depression Treatment and Satisfaction in a Multicultural Sample of Type 1 and Type 2 Diabetic Patients.
- Chromium Treatment Has No Effect in Patients With Poorly Controlled, Insulin-Treated Type 2 Diabetes in an Obese Western Population.
